- The 20th CPHI China in Shanghai
- CPHI China is a one-stop vertical trade and exchange event in the world-famous pharmaceutical industry.
- Shengnuo biotechnology participated in the 20th CPHI China in Shanghai
- The exhibition area of Sinochem is located in w4d08, with white and blue colors as the main colors, to highlight the purity and technology sense of pharmaceutical enterprises
The 20th CPHI China in Shanghai
The 20th world pharmaceutical raw materials China (CPHI China) was solemnly opened in Shanghai New International Expo Center on December 16, 2020. shengnuo biotechnology Chengdu was invited to participate in the grand event, and continued to explore a new double cycle journey of domestic and international pharmaceutical trade through the exhibition of enterprise products and technology and the expansion of business level.
Exploring the new journey of pharmaceutical industry of the year, shengnuo biotechnology participated in the 20th CPHI China
The 20th CPHI China in Shanghai
CPHI China is a one-stop vertical trade and exchange event in the world-famous pharmaceutical industry.
Following the domestic and international industry policies, grasping the new trends in the industry, and utilizing industry resources, CPHI China provides integrated solutions for professionals from pharmaceutical raw materials, contract customization, biopharmaceutical, pharmaceutical machinery, packaging materials and laboratory instruments.
The CPHI China attracted more than 300 overseas exhibitors from Germany, France, Switzerland, Italy and other countries to show on the same stage, providing convenience for domestic enterprises to find high-quality partners and introduce overseas products. And one belt, one road initiative will continue one after another to promote one’s “one belt, one road” state’s dealings with China’s pharmaceutical trade.
In addition, CPHI China will also hold more than 100 meetings and activities in the same period, from high-end forums to technology sharing seminars to complete the construction of business information exchange and trade negotiation platform.
Exploring the new journey of pharmaceutical industry of the year, shengnuo biotechnology participated in the 20th CPHI China
Shengnuo biotechnology participated in the 20th CPHI China in Shanghai
As one of the high-tech enterprises, shengnuo biotechnology owns Chengdu polypeptide drug Engineering Technology Research Center, and has a close relationship with foreign pharmaceutical peptide industry.
It not only has a cooperative relationship with Indian peptide production enterprises, but also has conducted training and production guidance for Indian medical enterprises through its own professional technology.
For shengnuo biotechnology, the international exhibition platform of CPHI China not only provides a platform for enterprises to display their own professional technology and high-quality products, but also provides an opportunity for insight into the global development trend of the industry and the operation mode of international industry.
The exhibition area of Sinochem is located in w4d08, with white and blue colors as the main colors, to highlight the purity and technology sense of pharmaceutical enterprises
During the exhibition, the exhibitors of shengnuo biotechnology actively publicized the company’s products, communicated face-to-face with partners and target customers. Through the interpretation of current professional technology and application analysis of various products, the visitors can have a more comprehensive and detailed understanding of the company’s situation.
At the same time, it also benefits the market promotion of shengnuo biotechnology products and technologies, and promotes the internationalization process of shengnuo biotechnology.
At the time of CPHI China’s 20-year-old, we hope that under the influence of CPHI China, more excellent pharmaceutical enterprises can emerge. At the same time, we hope that shengnuo biotechnology will run forward with an international vision, increase cooperation between domestic and foreign enterprises, and make more contributions to the world’s big health industry.